Published: March 10, 2020

Introduction {#sec1}
============

The conserved Target of Rapamycin (TOR) signaling pathway is a key regulator for cellular growth and metabolism in response to nutrients and energy ([@bib23], [@bib22], [@bib74], [@bib78]). TOR generally functions via two multi-protein complexes, TORC1 and TORC2, which coordinate distinct aspects of growth and associated processes ([@bib28], [@bib32]). TORC2 is not required for cell proliferation in fission yeast (*Schizosaccharomyces pombe*) but is required for sexual differentiation, stress response, and actin function ([@bib49], [@bib79]). TORC1 activates protein synthesis and other anabolic processes and inhibits autophagy and other catabolic processes. Active TORC1 functions on lysosomes, or vacuoles in yeast, in response to growth signals ([@bib4], [@bib13], [@bib56], [@bib73]).

In all organisms tested, TORC1 promotes aging and shortens lifespan ([@bib23], [@bib22], [@bib33], [@bib78]). Lifespan is influenced by multiple TORC1-dependent processes, including mitochondrial activity ([@bib29]), autophagy ([@bib65]), and protein translation ([@bib6], [@bib59]). Protein translation is controlled post-transcriptionally by TORC1 via phosphorylation of ribosomal S6 kinase (S6K) and the translation factors eIF2α and 4E-BP ([@bib42]). Inhibition of S6K can extend lifespan in several organisms ([@bib7], [@bib60], [@bib63], [@bib68]).

Besides post-transcriptional mechanisms, TORC1 promotes translational capacity and aging via transcriptional regulation ([@bib74]). It stimulates transcription of ribosomal RNAs via RNA polymerases I and III (RNA Pol I and RNA Pol III) ([@bib31]), although mechanisms are poorly understood. TORC1 may regulate RNA Pol I transcription via general transcription factors ([@bib26], [@bib50]). TORC1 also regulates the conserved Maf1 factor, which inhibits RNA Pol III ([@bib9], [@bib24], [@bib53], [@bib71], [@bib86], [@bib77]). RNA Pol III transcribes the highly abundant 5S ribosomal RNAs and transfer RNAs (tRNAs), which are central for translation, besides other small RNAs ([@bib1]). Given the focus on protein-coding gene transcription, the regulation of RNA Pol III transcription is less well understood. A recent study shows that RNA Pol III activity limits the lifespan downstream of TORC1 ([@bib21]). Altogether, these findings suggest that TORC1-mediated control of RNA Pol III transcription is universally important for translation and aging. However, no specific transcription factors have been identified that bind to RNA Pol III-dependent promoters and thus mediate translational control and lifespan.

The conserved *S. pombe* GATA transcription factor Gaf1 regulates responses to nitrogen limitation downstream of TORC1 ([@bib38]). Gaf1 can regulate gene expression either positively or negatively ([@bib36]). Here we show that Gaf1 is required for growth suppression upon TORC1 inhibition. Gaf1 binds not only to the promoters of certain protein-coding genes but also to the RNA Pol III-transcribed tRNA genes, which leads to their repression. Mutant cells lacking Gaf1 feature a shortened chronological lifespan. Our results uncover a transcription factor downstream of TORC1 that directly inhibits transcription of the tRNA genes, providing a mechanism for transcriptional control of global protein translation that prolongs lifespan.

Results and Discussion {#sec2}
======================

Genes Required for TOR-Mediated Growth Inhibition {#sec2.1}
-------------------------------------------------

TORC1 and TORC2 can be inhibited by Torin1, an ATP analog that blocks cell proliferation in *S. pombe* ([@bib2], [@bib72]). Using a low Torin1 dose (5 μM), *S. pombe* mutants have been screened for resistance and sensitivity to reduced TOR signaling ([@bib40]). Here we screened mutants under a four-fold higher Torin1 dose (20 μM). This dose blocked cell growth ([Figure 1](#fig1){ref-type="fig"}A) and reduced the size of both cells and vacuoles ([Figure 1](#fig1){ref-type="fig"}B). Global protein translation was also reduced by Torin1, as reflected by reduced phosphorylation of ribosomal S6 protein and increased total and phosphorylated eIF2α ([Figure 1](#fig1){ref-type="fig"}C). Altogether, these phenotypes look like those triggered by caffeine and rapamycin that block TORC1 function ([@bib59]). We conclude that Torin1 leads to phenotypes that are diagnostic for TORC1 inhibition.Figure 1Screen for Torin1-Resistant Mutants(A) Torin1 blocks cell proliferation. Top: ten-fold serial dilutions of wild-type (WT) cells spotted on rich solid medium. Bottom: growth profiles in rich liquid medium using a microfermentor, in the absence (control) and presence of Torin1.(B) Torin1 leads to decreased cell and vacuole sizes. Sizes of septated WT cells (top) and vacuoles (bottom) during Torin1 treatment.(C) Torin1 alters phosphorylation status of translational regulators. Phosphorylated (P) and total amounts (T) of ribosomal S6 and eIF2α proteins in WT cells following Torin1 treatment in rich (YES) or minimal (EMM2) media.(D) Design of genome-wide screens to identify mutants resistant to Torin1-mediated growth inhibition. We screened Bioneer version 2 (3,005 mutants) and Bioneer version 5 (3,420 mutants) of deletion libraries ([@bib88]) in two independent repeats each, using 20 μM Torin1 on rich solid medium (YES).(E) Example of deletion library plate with Torin1, containing 1,536 colonies with each mutant printed in quadruplicate. Red boxes indicate three Torin1-resistant mutants.(F) Torin1 sensitivity test using spotting assays for a WT control and the 19 resistant mutants identified, using different Torin1 concentrations as indicated. Red frames: 4 mutants showing strong resistance to all Torin1 concentrations tested.(G) Cellular processes associated with the 19 genes (red) required for Torin1-mediated growth inhibition.See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

We screened for deletion mutants that can suppress the strong growth inhibition by 20 μM Torin1 ([Figure 1](#fig1){ref-type="fig"}D). Overall, 19 mutants were resistant to Torin1-mediated growth inhibition in all 4 repeats ([Figure 1](#fig1){ref-type="fig"}E; [Table S1](#mmc1){ref-type="supplementary-material"}), 9 of which were identified in the previous screen ([@bib40]). We independently validated these 19 mutants, both by PCR and by backcrossing to a wild-type strain. The backcrossed mutants were spotted on Torin1 plates to confirm linkage of the drug-resistant phenotype to the deletion cassette. Although wild-type cells did not grow in Torin1, all 19 mutants managed to grow to various extents in different concentrations of Torin1 ([Figure 1](#fig1){ref-type="fig"}F). Four mutants were resistant to Torin1 at all concentrations, showing similar growth as on untreated medium ([Figure 1](#fig1){ref-type="fig"}F, red frames).

Some mutants feature resistance to multiple rather than specific drugs ([@bib17]). To exclude this possibility for the Torin1-resistant mutants, we assayed their growth in four other drugs; this analysis showed that all mutants were at least as sensitive to the other drugs as the wild-type control ([Figure S1](#mmc1){ref-type="supplementary-material"}A), indicating that their Torin1 resistance does not reflect multi-drug resistance. To exclude the possibility that resistance simply reflects that mutants cannot take up Torin1, we tested whether the Torin1-resistant mutants still showed other phenotypes of TORC1 inhibition ([Figures 1](#fig1){ref-type="fig"}B and 1C). The mutants still showed reduced ribosomal S6 protein phosphorylation after Torin1 treatment, except *aca1Δ* ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and decreased cell size ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These results indicate that Torin1 is taken up by the mutant cells, which differ in sensitivity to different TORC1 functions. Moreover, in all but the *aca1Δ* mutant, the growth resistance to Torin1 may be independent of translational control by ribosomal S6 phosphorylation.

The 19 genes identified in our screen function in limited cellular processes ([Figure 1](#fig1){ref-type="fig"}G; [Table S1](#mmc1){ref-type="supplementary-material"}). Vesicular transport and vacuolar functions were associated with 13 genes, 6 of which encode components of endosomal sorting complexes required for transport (ESCRT). Many of these proteins are part of the Nbr1-mediated vacuolar targeting (NVT) autophagic system ([@bib41]). The NVT pathway does not contain core Atg proteins but depends on ESCRTs and the multi-vesicular body to deliver soluble cargoes to the vacuole. How might vesicular transport and the NVT pathway relate to TOR signaling? Disruption of vesicle-mediated transport at the endosome triggers a metabolic signature similar to TORC1 inhibition ([@bib87]). It is possible that TORC1 controls the NVT pathway or that some of our mutants affect TORC1 localization to the vacuole, thus rendering the system resistant to Torin1 inhibition. A gene from the screen encodes the GATA transcription factor Gaf1. In budding yeast, components of Golgi-to-vacuole trafficking are required for TORC1-responsive regulation of GATA factors ([@bib20], [@bib57]). Given our interest in TORC1-dependent gene regulation and the strong Torin1-resistance of *gaf1Δ* mutants ([Figure 1](#fig1){ref-type="fig"}G), we further analyzed the function of Gaf1.

Gaf1 Is Required for Normal Lifespan and Lifespan Extension by Torin1 Treatment {#sec2.2}
-------------------------------------------------------------------------------

TORC1 inhibition through nutrient limitation or rapamycin prolongs chronological lifespan in *S. pombe* ([@bib59], [@bib60]), defined as the time post-mitotic cells remain viable in stationary phase. Given that Gaf1 is required to arrest growth upon TOR inhibition, we hypothesized that Gaf1 may also play a role in chronological lifespan. Indeed, *gaf1Δ* cells were shorter lived, with median and maximum lifespans of 3 and 16 days, respectively, compared with 5 and 20 days for wild-type cells ([Figure 2](#fig2){ref-type="fig"}). Thus, Gaf1 is required for the normal lifespan of non-dividing cells.Figure 2Gaf1 Is Required for Longevity(A) Chronological lifespan assays in WT and *gaf1Δ* cells grown in EMM2 in the absence or presence of 8 μM Torin1. Error bars represent SDs from 3 independent cell cultures, each measured 3 times per time point.(B) AUC for lifespan assays of WT and *gaf1Δ* mutant cells without or with Torin1 treatment. Vertical bars: Torin1-mediated increase in average AUC values for WT (black) and *gaf1Δ* (red), with the p value reflecting the significantly larger lifespan increase in WT than in *gaf1Δ* cells.

Torin1 increases lifespan in flies ([@bib47]) and suppresses senescence in human tissue cultures ([@bib39]). To analyze the effect of Torin1 on chronological lifespan in *S. pombe*, and any role of Gaf1 in this condition, we pre-treated exponentially growing wild-type and *gaf1Δ* cells with Torin1 and tested for subsequent effects on lifespan during the stationary phase. Torin1 substantially prolonged lifespan in wild-type cells, with median and maximum lifespans of 18 and 33 days, respectively, compared with 5 and 20 days in untreated cells ([Figure 2](#fig2){ref-type="fig"}A). In *gaf1Δ* cells, Torin1 also prolonged lifespan but to a lesser extent than in wild-type cells, with median and maximum lifespans of ∼13 and 30 days, respectively ([Figure 2](#fig2){ref-type="fig"}A). To quantify the role of Gaf1 in Torin1-mediated longevity, we calculated the areas under the curve (AUCs, measured as days × percentage of survival from lifespan assays). In wild-type cells, the lifespan was prolonged from an average AUC of 1,044 to 2,689 (increase of 1,645), whereas in *gaf1Δ* cells, the lifespan was prolonged to a lesser extent, from an average AUC of 681 to 1,709 (increase of 1,027) ([Figure 2](#fig2){ref-type="fig"}B). We conclude that Gaf1 is also required for the full lifespan extension resulting from Torin1-mediated TOR inhibition during cell proliferation. However, Torin1 still can prolong lifespan considerably without Gaf1, indicating that other factors contribute to this longevity. Indeed, we have identified several proteins required for lifespan extension when TORC1 is inhibited, including the S6K protein Sck2 ([@bib60]).

Gaf1-Dependent Transcriptome Regulation following TOR Inhibition {#sec2.3}
----------------------------------------------------------------

Given that Gaf1 was essential for growth inhibition by Torin1 ([Figure 1](#fig1){ref-type="fig"}G), we further analyzed its function in this condition. Gaf1 accumulated in the nucleus within a few minutes following treatment with Torin1 ([Figure 3](#fig3){ref-type="fig"}A) or with caffeine and rapamycin ([Figure S2](#mmc1){ref-type="supplementary-material"}), drugs that inhibit TORC1, but not TORC2 ([@bib59]). Consistently, Gaf1 is known to translocate to the nucleus during nitrogen limitation, which also inhibits TORC1, and biochemical analyses have shown that Gaf1 localization and phosphorylation depend on TORC1 activity ([@bib38], [@bib43]). This regulation of GATA transcription factors is conserved: budding yeast Gln3 and Gat1 ([@bib8]) and mammalian GATA6 ([@bib81]) are also sequestered in the cytoplasm by active TORC1 and translocate to the nucleus upon TORC1 inhibition.Figure 3Gaf1-Dependent Gene Expression(A) Top panels: fluorescence microscopy of cells expressing GFP-tagged Gaf1 (left) with chromatin stained by Hoechst 33342 (middle) after 10 min of exposure to 20 μM Torin1. Bottom panels: fluorescence microscopy of live Gaf1-GFP cells, showing stack projections of 1-min time lapses in rich medium. Cells are shown before (0 min) and in 1-min intervals after addition of either DMSO (solvent control; upper panels) or Torin1 (20 μM final; lower panels). Gaf1-GFP is visible inside the nucleus within 3 min after Torin1 addition. Scale bars: 5 μm. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(B) Hierarchical clustering of microarray data. Columns represent WT or *gaf1* mutants (*gaf1Δ*) before (untreated) and after 1 h of treatment with 20 μM Torin1 or with 10 mM caffeine and 100 ng/mL of rapamycin (Caff+Rap). Rows represent the 198 genes whose mRNA levels changed ≥1.5-fold in Torin1-treated *gaf1Δ* cells relative to WT cells, consisting of 90 genes showing higher expression (red bar) and 108 genes showing lower expression (blue bar) in *gaf1Δ* cells. In untreated cells, only 3 genes showed ≥1.5-fold expression changes in *gaf1Δ* relative to WT cells. Average RNA expression changes (from 2 independent repeats) in the different genetic and pharmacological conditions relative to WT control cells are color coded as shown. The orange bars indicate 43 genes whose promoters were bound by Gaf1 after 60 min with Torin1. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(C) Principal-component (PC) analysis of all genes measured by microarrays. PC1 separates untreated cells from cells treated with Torin1 (T) or caffeine and rapamycin (CT), while PC2 separates WT (blue) from *gaf1* mutants (*gaf1Δ*, red). Percentages of the x and y axes show the contribution of the corresponding PC to the difference in the data.

In *S. pombe*, Gaf1 activates genes functioning in amino-acid transport but represses *ste11*, encoding a master regulator for meiotic differentiation ([@bib36], [@bib43]). To systematically identify Gaf1-dependent transcripts, we performed microarray analyses of wild-type and *gaf1Δ* cells, both before and after Torin1 treatment. Before Torin1 treatment, wild-type and *gaf1Δ* cells showed similar expression signatures ([Figures 3](#fig3){ref-type="fig"}B and 3C). We conclude that in proliferating cells, Gaf1 plays no or a negligible role in gene regulation, consistent with its cytoplasmic localization when TORC1 is active ([Figure 3](#fig3){ref-type="fig"}A; [@bib38]).

However, Torin1 treatment resulted in substantial transcriptome changes in both wild-type and *gaf1Δ* cells, but in *gaf1Δ* cells, the expression signature markedly differed from the signature in wild-type cells ([Figures 3](#fig3){ref-type="fig"}B and 3C). Overall, 90 and 108 genes consistently showed ≥1.5-fold higher or lower expression, respectively, in *gaf1Δ* relative to wild-type cells after Torin1 treatment ([Figure 3](#fig3){ref-type="fig"}B; [Table S2](#mmc2){ref-type="supplementary-material"}). Cells treated with caffeine and rapamycin, which inhibit TORC1, but not TORC2 ([@bib59]), showed similar expression signatures as Torin1-treated cells in both wild-type and *gaf1Δ* cells ([Figures 3](#fig3){ref-type="fig"}B and 3C). This result indicates that the Torin1-mediated expression signatures in wild-type and *gaf1Δ* cells reflect TORC1 inhibition. We conclude that after TORC1 inhibition, Gaf1 affects the expression of ∼200 genes, either positively or negatively.

We performed functional enrichment analyses for these Gaf1-dependent genes using AnGeLi and g:profiler ([@bib5], [@bib62]). The 90 genes that were expressed higher in *gaf1Δ* than in wild-type cells (i.e., genes repressed by Gaf1) were typically downregulated in Torin1-treated wild-type cells but less so in *gaf1Δ* cells ([Figure 3](#fig3){ref-type="fig"}B). These genes were enriched in anabolic processes such as biosynthesis (61 genes, p = 9.4 × 10^−10^), ribosome biogenesis (19 genes, p = 1.6 × 10^−3^), and cytoplasmic translation (31 genes, p = 1.0 × 10^−16^), including 25 genes encoding ribosomal proteins. In budding yeast and worms, genetic inhibition of ribosomal proteins leads to lifespan extension ([@bib27], [@bib51]). [Figure S3](#mmc1){ref-type="supplementary-material"} visualizes all Gene Ontology (GO) biological processes enriched among the 90 genes. Many of these genes are also repressed as part of the core environmental stress response (43 genes, p = 1.4 × 10^−20^; [@bib11]) and are highly expressed in proliferating cells (mean of 46.9 mRNA copies/cell versus 7.5 copies for all mRNAs, p = 1.2 × 10^−26^; [@bib45]). We conclude that upon TORC1 inhibition, Gaf1 contributes to the downregulation of highly expressed genes functioning in protein synthesis.

The 108 genes that were expressed lower in *gaf1Δ* than in wild-type cells (i.e., genes induced by Gaf1) were typically upregulated in Torin1-treated wild-type cells but less so in *gaf1Δ* cells ([Figure 3](#fig3){ref-type="fig"}B). These genes were enriched in several metabolic processes of small molecules, including organonitrogen compounds (43 genes, p = 4.6 × 10^−14^), amino acids (18 genes, p = 4.1 × 10^−5^), urea (6 genes, p = 7.3 × 10^−5^), and organic acids (20 genes, p = 0.001) ([Figure S3](#mmc1){ref-type="supplementary-material"}). There was also a substantial overlap with genes that are induced by nitrogen limitation (43 genes, p = 1.3 × 10^−29^; [@bib48]) and genes that are periodically expressed during the cell cycle (41 genes, p = 1.6 × 10^−12^; [@bib44]), including 9 histone genes. These results suggest a Gaf1-dependent transcriptional program to adjust the metabolism of amino acids and other molecules, possibly to recycle nutrients under conditions that do not allow rapid proliferation. Similar gene-expression changes are mediated by budding yeast Gln3 and Gat1 under conditions of TORC1 inhibition ([@bib37], [@bib66]). Altogether, these findings indicate that Gaf1 regulates physiological changes supporting the growth arrest triggered by TORC1 inhibition.

Gaf1 Binds to Both Coding and tRNA Genes following TOR Inhibition {#sec2.4}
-----------------------------------------------------------------

The microarray analyses identified genes whose expression depends on Gaf1, some of which may be directly regulated by Gaf1. To detect gene promoters bound by Gaf1, we performed chromatin immunoprecipitation sequencing (ChIP-seq) of Gaf1-GFP cells. The number of Gaf1-bound promoters increased from 165 before Torin1 treatment to 454 after Torin1 treatment, with 93 genes in common between the two conditions ([Figure 4](#fig4){ref-type="fig"}A). Gaf1 binding sites upstream of close, divergently expressed genes were assigned to both genes. The Gaf1 target genes after Torin1 treatment consisted of 245 protein-coding genes and 209 non-coding genes ([Table S3](#mmc3){ref-type="supplementary-material"}).Figure 4Gaf1 Regulation of Protein-Coding and tRNA Genes(A) Gaf1 binding sites across the 3 *S. pombe* chromosomes, before (0 min, blue) and after (60 min, orange) treatment with 20 μM Torin1. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.(B) Hierarchical clustering of microarray data for 150 protein-coding genes bound by Gaf1 after Torin1 treatment and for which expression data were available for all conditions. The conditions have been clustered as well (red tree on top) and are grouped as follows: untreated WT and *gaf1Δ* cells (U*wt*, U*gaf1*), caffeine+rapamycin- or Torin1-treated *gaf1Δ* cells (CR*gaf1*, T*gaf1*), and caffeine+rapamycin- or Torin1-treated WT cells (*CRwt*, T*wt*). Expression changes are color coded as in [Figure 3](#fig3){ref-type="fig"}B.(C) Gaf1 shows increased binding to tRNA genes after Torin1 treatment. Top, red curves: average Gaf1 binding profiles aligned to transcription start sites (TSSs) of all *S. pombe* tRNA genes before (0 min) and after (60 min) Torin1 treatment, along with corresponding control ChIP-seq data (hemagglutinin \[HA\]). Bottom: heatmaps of Gaf1 binding around the TSS of all 196 tRNAs, ordered by normalized ChIP-seq coverage. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.(D) Northern blots of precursor tRNAs for leucine (top) and asparagine (middle) from WT and *gaf1Δ* cells, treated with 20 μM Torin1 over 120 min as indicated. Probes to detect precursor tRNAs, indicated with red bars, are as described before ([@bib55]). Probes for *cdc2* were used as loading control (bottom).(E) Northern quantitation of leucine and asparagine precursor tRNAs relative to WT time 0 and normalized to loading controls (three independent repeats shown as dots). Asterisks denote significant differences in pre-tRNA levels between WT and *gaf1Δ* cells from same time point (t test, p \< 0.05).(F) Model for Gaf1-mediated transcriptional repression of translation downstream of TORC1. Following TORC1 inhibition, Gaf1 activates the transcription of genes for small-molecule metabolic pathways and represses the transcription of tRNAs and other genes functioning in translation (the latter via indirect control, hatched). Together with the S6K-mediated translational control ([@bib42]), this transcriptional branch contributes to longevity.

The protein-coding Gaf1 target genes were significantly enriched in metabolic processes of organonitrogen compounds (55 genes, p = 1.4 × 10^−6^), including nucleotides (24 genes, p = 0.0009) and organic acids (34 genes, p = 0.0003) ([Figure S4](#mmc1){ref-type="supplementary-material"}). They were also enriched for genes induced by nitrogen limitation (40 genes, p = 1.6 × 10^−11^) and periodically expressed during the cell cycle (53 genes, p = 4.5 × 10^−6^). Overall, these target genes showed similar functional enrichments to the genes whose expression was induced by Gaf1. Accordingly, Gaf1 binding sites were enriched among the genes induced by Gaf1 ([Figure 3](#fig3){ref-type="fig"}B, orange bars). Moreover, most protein-coding genes bound by Gaf1 were induced by TORC1 inhibition but less so in *gaf1Δ* cells, leading to distinct clusters for wild-type and mutant conditions ([Figure 4](#fig4){ref-type="fig"}B). We conclude that coding Gaf1 target genes are mostly upregulated by Gaf1 when TORC1 is inhibited.

Notably, Gaf1 bound to the promoters of 20 transcription factor genes ([Table S3](#mmc3){ref-type="supplementary-material"}; [Figure S4](#mmc1){ref-type="supplementary-material"}). Typically, these factors were induced in wild-type cells after TORC1 inhibition but less so in *gaf1Δ* cells. Many of these factors are involved in stress responses or cell-cycle regulation, including Atf1 ([@bib80]), Cbf12 ([@bib11]), Fep1 ([@bib3]), Fil1 ([@bib19]), Hsr1 ([@bib12]), Klf1 ([@bib70]), Loz1 ([@bib16]), Pap1 ([@bib12]), Php3 ([@bib52]), and Sep1 ([@bib64]). These transcription-factor targets indicate that Gaf1 may indirectly control some Gaf1-dependent genes via other transcription factors. Gaf1 inhibited the expression of many genes functioning in translation ([Figure S3](#mmc1){ref-type="supplementary-material"}), but these genes were not among its direct binding targets. These genes may thus be indirectly regulated by Gaf1; for example, Atf1 represses translation-related genes during stress ([@bib12]), raising the possibility that it also represses these genes during TORC1 inhibition in a Gaf1-dependent manner.

The 209 non-coding genes among the Gaf1 targets included 82 tRNA genes and a small nucleolar RNA (snoRNA) involved in tRNA regulation, besides large non-coding RNAs ([Table S3](#mmc3){ref-type="supplementary-material"}). Coverage plotting indicated that Gaf1 binds to all tRNA genes that are clustered in *S. pombe* ([Figure 4](#fig4){ref-type="fig"}C; [Figure S5](#mmc1){ref-type="supplementary-material"}). Binding occurred near the transcription start sites for tRNA genes and strongly increased after Torin1 treatment ([Figure 4](#fig4){ref-type="fig"}C). We conclude that Gaf1 binds not only to genes transcribed by RNA Pol II but also to the tRNA genes transcribed by RNA Pol III. To address whether Gaf1 represses or activates tRNAs, we performed northern analyses of tRNA gene expression as a function of Gaf1 and Torin1. The abundant mature tRNAs are rapidly processed from precursor tRNAs, which need to be assayed to detect expression changes ([@bib55]). The expression of tRNA precursors decreased during Torin1 treatment in wild-type cells, while in *gaf1Δ* cells their expression was higher and showed a delayed and less pronounced decrease, especially at later time points ([Figures 4](#fig4){ref-type="fig"}D and 4E). We conclude that Gaf1 binds to tRNA genes and inhibits their expression upon TOR inhibition.

Downregulation of precursor tRNA expression is required for TORC1 inhibition in *S. pombe* ([@bib55]), indicating that tRNAs can act upstream of TORC1. Our experiments, conversely, point to a mechanism of tRNA regulation downstream of TORC1. Altogether, these findings suggest regulatory feedback, involving precursor tRNAs, TORC1, and Gaf1, to match tRNA expression to physiological requirements. Our results reveal a transcription factor that not only controls RNA Pol II-mediated expression of genes functioning in translation- and metabolism-related processes but also globally inhibits RNA Pol III-mediated expression of tRNAs. It will be interesting to test whether the latter function is conserved for orthologous GATA transcription factors. Studies of Gln3 and Gat1 function in budding yeast have excluded tRNAs and are therefore not conclusive with respect to tRNA gene regulation ([@bib37], [@bib66]).

Conclusions {#sec2.5}
-----------

The GATA transcription factor Gaf1 is essential for blocking cell proliferation with Torin1; in its absence, cell growth remains normal, even in high doses of Torin1 ([Figure 1](#fig1){ref-type="fig"}G). Gaf1 is also required for normal chronological lifespan and contributes to, but is not necessary for, the longevity of Torin1-treated cells ([Figure 2](#fig2){ref-type="fig"}). Upon TORC1 inhibition, Gaf1 inhibits the expression of genes functioning in protein translation, including protein-coding genes, which may be indirectly controlled by Gaf1, and tRNA genes, which are binding targets of Gaf1 ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Gaf1 also positively controls genes functioning in metabolic pathways for nitrogen-containing molecules, which support the adaptation to lowered protein synthesis. Thus, Gaf1 can directly regulate both RNA Pol II- and RNA Pol III-transcribed genes. It is possible that Gaf1 elicits its repressor activity at tRNA genes by recruiting a histone deacetylase: work in *S. pombe* has identified potential loading sites for Clr6 complex components at tRNAs ([@bib85]). Downregulation of global protein translation is beneficial for longevity in all organisms studied, including *S. pombe* ([@bib34], [@bib58]). Given its role in repressing diverse translation-related factors, Gaf1 may inhibit aging by contributing to the downregulation of translation upon TORC1 inhibition ([Figure 4](#fig4){ref-type="fig"}F). Gaf1 thus defines a transcription-based branch of translational and metabolic control downstream of TORC1, in parallel to the post-translational branch exerted by translational regulators like S6K ([Figure 4](#fig4){ref-type="fig"}F). This transcriptional branch is essential for growth inhibition triggered by lowered TORC1 activity.

Repression of RNA Pol III prolongs lifespan in yeast, worms, and flies and is required for the lifespan extension mediated by TORC1 inhibition ([@bib21]). Besides general transcription factors such as TFIIIB, TFIIIC, and TBP, several factors control RNA Pol III transcription without directly binding to DNA ([@bib30]), including the RNA Pol III inhibitor Maf1, the coactivator PNRC, and MYC, which interacts with the RNA Pol III basal apparatus ([@bib10], [@bib24], [@bib83]). To our knowledge, the TORC1 target Gaf1 is the first specific transcription factor shown to globally bind to and repress the tRNA genes. Thus, Gaf1 could exert the aging-associated function of RNA Pol III. Recent work in flies shows that GATA transcription factors can mediate the effects of dietary restriction on lifespan ([@bib18]). This finding raises the possibility that Gaf1 regulation of aging-related processes is conserved and that other GATA factors exert similar functions downstream of TORC1. The mouse and human ortholog of Gaf1, GATA6, is involved in differentiation, stem cell maintenance, and cancer ([@bib75], [@bib76], [@bib82]). It is plausible that GATA6 exerts these important functions by regulating translation-related genes, including tRNAs.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Phospho-(Ser/Thr) Akt Substrate (PAS)Cell SignalingCat\#9611; RRID:[AB_330302](nif-antibody:AB_330302){#interref65}Anti-rps6AbcamCat\#ab40820; RRID:[AB_945319](nif-antibody:AB_945319){#interref70}anti-rabbit HRPAbcamCat\#ab6721; RRID:[AB_955447](nif-antibody:AB_955447){#interref75}Anti-GFPAbcamCat\#ab290; RRID:[AB_303395](nif-antibody:AB_303395){#interref80}Anti-HAAbcamCat\#ab9110; RRID:[AB_307019](nif-antibody:AB_307019){#interref85}Dynabeads M-280 sheep anti Rabbit IgGThermo FisherCat\# 11203D; RRID:[AB_2783009](nif-antibody:AB_2783009){#interref90}**Chemicals, Peptides, and Recombinant Proteins**RapamycinLC Laboratories\# R-5000CaffeineSigma\# 27602-250GTorin1TOCRIS\#4247FM4-64ThermoFisher\#T13320CalcuofluorSigma\#18909Doxycycline hyclateSigma\# D9891CdSO4Sigma\# 202924CycloheximideSigma\# C7698PMSFSigma\#10837091001Phosphatase Inhibitor Cocktail 1Sigma\#P2850Phosphatase Inhibitor Cocktail 2Sigma\#P5726Complete, EDTA free protease Inhibitor CocktailMerck\#11873580001**Critical Commercial Assays**MicroarraysAgilentCustom design 8x15KNEBNext® ultra DNA Library Prep kitNew England BiolabsE7370LECL Western Blotting Detection SystemGE HealthcareGERPN2134DIG Oligonucleotide 3′ End Labeling Kit, 2nd generationMerk\#03353575910DIG Luminescent Detection KitMerk\# 11363514910DIG Wash and Block Buffer SetMerk\# 11585762001BrightStar-Plus Positively Charged Nylon MembraneThermo Fisher\# AM10100Mini-PROTEAN® TBE-Urea Precast GelsBio Rad\# 4566036MiSeq Reagent Kit v3 (150-cycle)IlluminaMS-102-3001**Deposited Data**ChIP-seq dataENAAccession numbers: PRJEB32910 and ERP115647Microarray dataArrayExpressAccession number: E-MTAB-8569**Experimental Models: Organisms/Strains**Fission yeast 972^-^Bahler lab strainlistJB903Fission yeast Gaf1-GFPBahler lab strainlistJB1744Fission yeast Bioneer strainsBioneerN/A**Oligonucleotides**Cdc-SRTcdc2-SRT GGGCAGGGTCATAAACAAGC[@bib14]tRNA-leu-CAA-intron-5GACTATCGTCCAAGTATTACTTGAGTGCTGCG[@bib55]tRNA-asn01-5leaderTATGCTACCCGACCTATAATGCTCCTGGTGAG[@bib55]**Software and Algorithms**ImageJ[@bib89]<https://imagej.nih.gov/ij/>Volocity acquisition programPerkinElmer<https://www.perkinelmer.com/>Volocity quantitation packagePerkinElmer<https://www.perkinelmer.com/>GEM[@bib25]<http://groups.csail.mit.edu/cgs/gem/>Bowtie2[@bib90]<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>ChIPpeakAnno[@bib84]<https://www.bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html>Deeptools[@bib61]<https://deeptools.readthedocs.io/en/develop/>Samtools[@bib91]<http://samtools.sourceforge.net/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jürg Bähler (<j.bahler@ucl.ac.uk>). This study generated new *S. pombe* strains that are available from the Lead Contact without restriction upon request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

This study has been conducted using *S. pombe* as experimental model. For wild-type control strains, we used *972 h*^*-*^ or the parental strains for the deletion library, ED666 (*h+ ade6-M210 ura4-D18 leu1--32*) and ED668 (*h+ ade6- M216 ura4-D18 leu1--32*). The Bioneer haploid deletion library strains used for further studies were PCR-validated and backcrossed with *972 h*^*-*^. The *gaf1-GFP* strain was generated as described ([@bib92]). Cell cultures were grown in yeast extract plus supplements (YES) as default or in Edinburgh minimal medium (EMM2) if indicated ([@bib54]). Liquid cultures were grown at 32°C with shaking at 130 rotations per minute.

Method Details {#sec4.4}
--------------

### Drug sensitivity assays {#sec4.4.1}

Cells were grown in liquid YES to an OD~600~ of 0.5. Ten-fold serial dilutions of cells were spotted onto YES agar plates, using replica platers for 48-well or 96-well plates (Sigma), with or without drugs as indicated in figure legends.

### Measurement of cell size and fluorescence microscopy {#sec4.4.2}

To determine cell size, control and drug-treated cells were fixed in 4% formaldehyde for 10 min at room temperature, washed with 50 mM sodium citrate, 100 mM sodium phosphate, and stained with Calcofluor (50 mg/ml). Microscopy was performed using a DAPI filter for Calcofluor detection and a Hamamatsu ORCA-ER C4742-95 digital camera fitted to a Zeiss Axioskop microscope with EC plan-NEOFLUAR 63x 1.25 NA oil objective. Images were recorded using the Volocity acquisition program (PerkinElmer). At least 100 septated cells were counted and analyzed for each condition using the Volocity quantitation package (PerkinElmer). Results were analyzed in R. For fluorescence microscopy of Gaf1-GFP cells, we used a spinning disk confocal microscope (Yokogawa CSU-X1 head mounted on Olympus body; CoolSnap HQ2 camera \[Roper Scientific\], Plan Apochromat 100X, 1.4 NA objective \[Olympus\]). The images correspond to maximum intensity projections of 15 image stacks with a Z-step of 0.3 microns. Cells were immobilized with soybean lectin (Sigma L1395) in two different compartments of a glass-bottom 15 μ-Slide 8 well (Ibidi 80821) to add either DMSO as a solvent control or Torin1 (to a final concentration of 20 μM, dissolved in DMSO). *In vivo* chromatin staining was done with Hoechst 33342 (1 μg/ml). As this dye performs poorly in YES, cells were immobilized onto glass bottom wells and washed three times with liquid EMM2 containing Hoechst 33342 (Sigma-Aldrich B2261) at 1 μg/ml plus Torin1 (20 μM). Cells were covered with this media and imaged 10 min later. Image analysis and editing was performed using Fiji (ImageJ) open software ([@bib67]).

### Measurement of vacuolar size {#sec4.4.3}

Vacuolar labeling was performed as described ([@bib15]). Briefly, FM4-64 dye (Molecular Probes) was dissolved in DMSO at a concentration of 0.82 mM, and 2 μL FM4-64 stock was added to 1 mL log-phase cells with or without drugs. Following 30 min exposure to FM4-64, cells were washed and chased for 40 min in fresh media to allow all dye to reach the vacuole. Fluorescence microscopy was performed using a Rhodamine filter for detection of FM4-64 and a Hamamatsu ORCA-ER C4742-95 digital camera fitted to a Zeiss Axioskop microscope with EC plan-NEOFLUAR × 63 1.25 NA oil objective. Images were recorded using the Volocity acquisition program (PerkinElmer). At least 500 vacuoles were measured using the Volocity quantitation package (PerkinElmer). Results were analyzed in R.

### Chronological lifespan assay {#sec4.4.4}

Cells were grown in EMM2 media as described ([@bib59]). When cultures reached a stable maximal density, cells were left an additional 24 hr and then harvested, serially diluted, and incubated on YES plates. The measurement of colony-forming units (CFUs) was taken at the beginning of the lifespan curve (time point 0: 100% cell survival). CFU measurements were conducted on successive days until cultures dropped to 0.1% cell survival. Error bars represent standard deviation calculated from three independent cultures, with each culture measured three times at each time point. To determine the chronological lifespan when TOR is inhibited, 8 μM Torin1 was added to rapidly proliferating cell cultures at OD~600~ = 0.5 which were then grown to stationary phase, and lifespan was recorded as described above. AUCs were measured with ImageJ ([@bib67]) for all experimental repeats using lifespans curves on the linear scale for % survival.

### High-throughput genetic screening {#sec4.4.5}

The haploid deletion libraries were plated onto YES plates containing 100 μg/ml G418 using a RoToR HDA robot (Singer). Multiple replicate copies of the library were thus generated. Using the RoToR, the libraries were compacted into nine 384-density plates of plates and then printed onto plates containing 20 μM Torin1. The plates were incubated at 32°C for 2 days and then manually scored for resistant colonies.

### Growth assay {#sec4.4.6}

Growth in the presence or absence of Torin1 were automatically determined in 48-well flowerplates at 1.5 mL volumes, 1000 rpm and 32°C using the Biolector microfermentation system (m2p-biolabs). Growth dynamics were modeled using the grofit R package ([@bib35]). In the resulting growth curves, the units of the x axis are time (hr) while the y axis shows biomass (arbitrary units) normalized to biomass at time 0.

### Western blotting and antibodies {#sec4.4.7}

For protein preparations, cells were diluted in 6 mM Na~2~HPO~4~, 4mM NaH~2~PO~4~.H~2~O, 1% Nonidet P-40, 150 mM NaCl, 2 mM EDTA, 50 mM NaF supplemented with protease (PMSF) and phosphatase inhibitors (Sigma cocktails 1 and 2), together with glass beads. Cells were lysed in a Fastprep-24 machine (MP Biomedicals). Phospho-(Ser/Thr) Akt Substrate (PAS) Antibody (9611, Cell Signaling) for detection of P-S6 (p27) and anti-rps6 (ab40820, Abcam) were used at 1/2000 dilution. For detection, we used the anti-rabbit HRP-conjugated antibody (1/5000 dilutions) with the ECL Western Blotting Detection System (GE Healthcare) according to the manufacturer's protocol.

### Microarrays {#sec4.4.8}

Microarray analysis was performed as previously described ([@bib59]). Cells were grown in YES to OD~600~ = 0.5 and harvested. Torin1 treatments were done for 1 hr at a concentration of 20 μM. Caffeine/rapamycin treatments were also performed for 1 hr at concentrations 10mM caffeine and 100ng/ml rapamycin. Two independent biological repeats with a dye swap were performed. For each repeat, a corresponding pool of Torin1 or caffeine/rapamycin treated and untreated wild-type and *gaf1Δ* cells was used as a common reference for microarray hybridization. Agilent 8 × 15K custom-made *S. pombe* expression microarrays were used, with hybridizations and subsequent washes performed according to the manufacturer's protocols. The microarrays were scanned and extracted using GenePix (Molecular Devices), processed using R scripts for quality control and normalization, and analyzed using GeneSpring GX3 (Agilent). We determined genes that were 1.5-fold upregulated or downregulated in both repeats of Torin1-treated and caffeine/rapamycin-treated *gaf1Δ* cells relative to Torin1-treated and caffeine/rapamycin-treated wild-type cells respectively.

### ChIP-seq {#sec4.4.9}

Cells were grown in YES to an OD~600~ of ∼0.4. Untreated and Torin 1-treated (20 μM for 15 min or 1 hr) cells were fixed in 1% formaldehyde for 30 min and then quenched 10 min with 125mM glycine. Pellets were washed with ice-cold PBS, snap frozen in liquid nitrogen and stored at −80°C. Cell pellets were resuspended in lysis buffer (50 mM HEPES pH 7.6, 1mM EDTA pH 8, 150 mM NaCl, 1% Triton X-100, 0.1% sodium doxycolate, 1mM PMSF and protease inhibitors). Chromatin was obtained following cell disruption using a Fastprep-24 (MP Biomedicals) and sheared using a Bioruptor (Diagenode). Dynabeads M-280 sheep anti-rabbit IgG were incubated in lysis buffer and 0.5% BSA for 2 hr with either rabbit anti-GFP (Abcam) for query IPs or 5 μl of rabbit-anti HA (Abcam) for control IPs. Then, 2 mg of Chromatin extract were inmunoprecipitated for 16 hr using the corresponding antibody-incubated Dynabeads. Following the washes, DNA was eluted, treated with RNase and proteinase K, and purified using the QIAGEN PCR MiniElute kit. Sequencing libraries were prepared using the NEBNext® ultra DNA Library Prep kit for Illumina® (E7370L). DNA was sequenced using Illumina Mi-seq with a V3 kit, sequencing 75 bp on each end. Sequences were aligned to the *S. pombe* genome build ASM294v2 using Bowtie2. Peak calling was done with GEM ([@bib25]) (setting--k_min 4 and--k_max 18), and peak annotation was done with the R package ChIPpeakAnno ([@bib84]). Peaks were annotated to the closest TSS; for peaks lying within 500 bp of 2 divergently expressed genes, peaks were annotated to both genes. Normalizations for the plots were performed using deeptools ([@bib61]) (normalizing to RPGC and using the parameters --centerReads --binsize 10 --smoothLength 2). Further analyses were carried out with R scripts (<http://www.r-project.org/>). Gene enrichment analysis was performed using AnGeLi ([@bib5]) and g:profiler ([@bib62]).

### Northern analyses {#sec4.4.10}

Detection of tRNA precursors was performed as described ([@bib55]) using Digoxigenin labeled probes (Roche), following the manufacturer's instructions. As a loading control, northerns were stripped by incubating for 60 min at 60°C with 0.1% SDS, changing the solution every 10 min, followed by re-hybridizing with a Digoxigenin labeled probe specific for *cdc2* (cdc2-SRT GGGCAGGGTCATAAACAAGC) as described ([@bib14]). Quantification of Northern blots has been performed by ImageJ ([@bib67]) as previously described ([@bib60]). Ratios of each tRNA band signal with the corresponding *cdc2* loading control have been normalized with the ratio at time point 0 for each tRNA and genotype.

Quantification and statistical analysis {#sec4.5}
---------------------------------------

Northern blot and lifespan AUC quantification has been conducted using ImageJ using 3 independent biological repeats (n = 3). Significance has been defined using t tests with a p value cutoff of 0.05. Microarray experiments have been conducted in 2 biological repeats with a dye swap. ChIP-seq experiments have been conducted in 2 biological repeats. Quantifications and statistical analysis are also described in corresponding [STAR Methods](#sec4){ref-type="sec"} sections. Lifespan assays have been performed in three biological repeats with each time point measured in three technical repeats for each biological replicate. t tests were used for AUC statistics. For [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}, p values refer to adjusted p values using the g:SCS algorithm described in the g:profiler software ([@bib62]). For [Figure 1](#fig1){ref-type="fig"}B, each boxplot represents at least 500 measured vacuoles. In [Figure S1](#mmc1){ref-type="supplementary-material"}, each boxplot represents at least 100 measured cells.

Data and Code Availability {#sec4.6}
--------------------------

### Scripts for Analysis {#sec4.6.1}

Scripts, packages and programs used for analyses are mentioned in the main text and listed within the [Key Resources Table](#sec4.1){ref-type="sec"}.

### Dataset Hosting {#sec4.6.2}

The accession numbers for the ChIP-seq data reported in this paper are ENA: PRJEB32910 and ERP115647. The accession number for the microarray data reported in this paper is ArrayExpress: [E-MTAB-8569](array-express:E-MTAB-8569){#interref95}.
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